SN52 |
رقم الكتالوجGC19806 |
SN52 هو مثبط قوي وتنافسي ومنفذ للخلايا لـ NF-κB2. SN52 هو نوع من الببتيد SN50 ويمنع الانتقال النووي لمغاير p52-RelB. SN52 له تأثير تحسس إشعاعي قوي على خلايا سرطان البروستاتا. يمكن استخدام SN52 في أبحاث السرطان.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1071173-56-2
Sample solution is provided at 25 µL, 10mM.
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research.
IC50 & Target
IC50: NF-κB2
(In Vitro)
SN52 (40 μg/ml; 30 mins before DMXAA) inhibits DMXAA-induced nuclear translocation of RelB in BMDCs[1].
SN52 does not change the activation of canonical NF-κB signaling. The nuclear translocation of RelB is increased in DCs isolated from irradiated tumors, and SN52 abolishes this activation in activated DC cells[1].
SN52 (40 μg/mL; 30 mins before co-cultured with irradiated or non-irradiated MC38 cells) inhibits the non-canonical NF-κB and increases Ifn-b expression in BMDCs stimulated with irradiated tumor cells.
(In Vivo)
SN52 (intrathecal injection; 40 μg/ml; day-1, day 1 and day 3 of 20Gy radiation of radiation) combines with IR enhances anti-tumor immune functions of both DCs and CD8+ T cells and subsequently reduced tumor burden more effectively compared with IR alone[1].
Animal Model: Tumor mice model
Dosage: 40 μg
Administration: Intrathecal injection; 40 μg; day-1, day 1 and day 3 of 20Gy radiation of radiation
Result: Reduced tumor burden than IR group alone.
Induced non-canonical NF-κB inhibition and potentiates the anti-tumor effect of IR.
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *